Essix Biosciences acquires 70 lakh FCWs in Ind-Swift Laboratories
- Essix Biosciences acquired 70 lakh FCWs via preferential issue on September 17, 2026
- The transaction raises the promoter group's diluted stake to 47.18%
- Essix Biosciences holds 3.28 crore shares plus the new warrants
- PACs retain a 4.74% diluted stake through their existing shareholding

*this image is generated using AI for illustrative purposes only.
Promoter group entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants (FCWs) in Ind-Swift Laboratories through a preferential issue on September 17, 2026. The transaction strengthens the promoter group’s consolidated diluted stake to 47.18%.
The acquisition was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Essix Biosciences, acting on behalf of the promoter and promoter group, purchased the warrants for cash. Each warrant is convertible into one equity share with a face value of ₹10.
Holding Structure Changes
Before this transaction, Essix Biosciences held 3,28,82,521 shares, representing 37.92% of the total voting capital. Persons Acting in Concert (PACs), comprising family members and associates including Gopal Munjal and Himanshu Jain, held 44,51,757 shares (5.13%). The combined pre-acquisition holding stood at 43.06%.
Following the allotment of the FCWs, the total diluted share capital of Ind-Swift Laboratories increased to 9,39,61,558 equity shares. The post-acquisition structure reflects the following positions:
| Stakeholder | Shares Held | Diluted Holding % |
|---|---|---|
| Essix Biosciences Ltd | 3,28,82,521 shares + 70,00,000 FCWs | 42.45% (35.00% + 7.45%) |
| PACs | 44,51,757 shares | 4.74% |
| Total Promoter Group | 4,43,34,278 instruments | 47.18% |
Note: Essix Biosciences' diluted percentage combines its direct shareholding (35.00%) and the warrant conversion potential (7.45%).
What the Numbers Show
The acquisition highlights a strategic shift towards dilutive financing for the promoter group. While the absolute number of equity shares held by Essix Biosciences remained unchanged at 3,28,82,521, its effective control expanded via the addition of 70,00,000 convertible instruments. This increased the total instrument count held by the acquirer to 4,43,34,278, pushing the consolidated diluted stake from 43.06% to 47.18%. The use of FCWs allows the promoters to increase their voting power exposure without immediate cash outlay for full equity shares, though it introduces future dilution pressure upon conversion.
Historical Stock Returns for Ind Swift Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.65% | -1.54% | +9.38% | +160.94% | +258.57% | 0.0% |
What is the conversion price and expiry date of the newly issued FCWs, and how does this valuation compare to Ind-Swift's current market price?
How will the eventual conversion of these 70 lakh warrants impact existing minority shareholders' equity and earnings per share (EPS)?
Does this preferential issue trigger any open offer obligations under SEBI takeover regulations, or does it fall within the exemption thresholds?


































